Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4157-4165
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4157
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4157
Table 4 Comparison of adverse reaction occurrence between the two groups, n (%)
Adverse reaction | Control group, n = 36 | Joint group, n = 38 | χ2 | P value |
Embolism syndrome | 0 (0) | 2 (5.26) | ||
Fatigue | 1 (2.78) | 1 (2.63) | ||
Abnormal liver function | 2 (5.56) | 1 (2.63) | ||
Rash | 1 (2.78) | 2 (5.26) | ||
Bone marrow suppression | 0 (0) | 1 (2.63) | ||
Gastrointestinal reaction | 2 (5.56) | 2 (5.26) | ||
Hand-foot syndrome | 1 (2.78) | 2 (5.26) | ||
Total incidence | 7 (19.44) | 11 (28.95) | 0.907 | 0.341 |
- Citation: Qi JS, Zhao P, Zhao XB, Zhao YL, Guo YC. Small particle drug-eluting beads-transarterial chemoembolization combined with targeted therapy in the clinical treatment of unresectable liver cancer. World J Gastrointest Oncol 2024; 16(10): 4157-4165
- URL: https://www.wjgnet.com/1948-5204/full/v16/i10/4157.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i10.4157